(Date:9/5/2008)...ashington, DCWomen with hormone-receptor positive,... years to help keep their cancer at bay, but when ..., treatment with chemotherapy becomes the only opt...Breast Cancer Symposiummay change this approach. ...re-sensitize" the tumor, allowing anti-hormonal dr...
(Date:9/4/2008)...INSTON-SALEM, N.C. Free drug samples provided to ...lly be costing uninsured patients more in the long...Wake Forest University Baptist Medical Center and ...the prescribing habits of more than 70 physicians ...ice in the months immediately before and after the...
(Date:9/4/2008)...erts develop sequence of instructions they say cou...DAY, Sept. 4 (HealthDay News) -- Vaccine safety ex... vaccines can receive vaccinations with close moni...porting in the September issue of Pediatrics , a ...s Center put forth a step-by-step set of instructi...
(Date:9/4/2008)...echnical and Naturals Pavilions are Sold-Out and S...Well-Represented, NEW YORK, Sept. 4 /PRNewswire/ ...cal equipment, naturals products, and sustainable,...po (http://www.hbaexpo.com ),September 9, 10, 11...ork.,Both the Technical and Naturals Pavilions at ...
Breaking Medicine News(10 mins):Health News:1 step back ... 2 steps forward 2Health News:Free drug samples may end up costing uninsured more 2Health News:Free drug samples may end up costing uninsured more 3Health News:Even Kids With Known Allergies Can Be Safely Vaccinated 2Health News:HBA Exhibit Floor Offers Global Resources to the Beauty and Personal Care Industry 2Health News:HBA Exhibit Floor Offers Global Resources to the Beauty and Personal Care Industry 3...rs have identified a key receptor that could be a ...f acute respiratory distress syndrome (ARDS). //Th...tening condition. The receptor is similar to wha... taste (G-protein coupled receptors) There is no e...
...e Prime Minister Mr. Man Mohan Singh to take the i...he films and television. // With the ministries of...o reach consensus on modalities for implementing t...ter approached Prime Minister Manmohan Singh to re...
...be able to isolates molecule that would be helpful...volutionary study has been done independently by t...spital Boston and they have identified a master pr...change as a result of individual experiences. Sci...
...rnment on Wednesday for neglecting their duties ac... of Bihar Mr. Nitish Kumar gave the nod for the di...ried out with immediate effect. Last week, the go...edical officers and initiated departmental proceed...
Other Medicine News:(Date:9/3/2008)... that Multaq(R) (dronedarone) decreased the risk o...n or atrial flutter already adequatel... N.J., Sept. 3 /- The resul...ENA study were presented today at,the clinical tri...ology,congress 2008, in Munich, Germany. Previous ...
(Date:9/3/2008)...erations, Updates Zingo Launch Progress and Adlea ... Conference Call Today at 11:30 am ET,...-FirstCall/ -- Anesiva,Inc. (Nasdaq: ANSV ) anno...ations to focus on commercial and late-stage produ...pecialty pharmaceutical pain management,company. T...
(Date:9/3/2008)...uated in Repeat-Dosing Study in Subjects with ALS,... -- Sangamo,BioSciences, Inc. (Nasdaq: SGMO ) ann... trial (SB-509-801) to evaluate its drug, SB-509, ...motor-neuron disease for which there,are limited t...-509, is an injectable formulation of a plasmid,en...
(Date:9/2/2008).../- Forest Laboratories, Inc...day announced results from,two global Phase III st...nhaled anticholinergic for the treatment of patien...D). In both the ACCLAIM/COPD I&II,(AClidinium CLin...te to,Severe COPD Patients) studies, once-daily ac...
Breaking Medicine Technology:Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 2Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 3Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 5Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 2Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 3Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 4Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 5Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 6Gerber Scientific to Present at 10th Annual Needham Growth Stock Conference 9000 1Gerber Scientific to Present at 10th Annual Needham Growth Stock Conference 9000 2Transcript of Elizabeth Mazzocchi Press Conference 8996 1Transcript of Elizabeth Mazzocchi Press Conference 8996 2Transcript of Elizabeth Mazzocchi Press Conference 8996 3Transcript of Elizabeth Mazzocchi Press Conference 8996 4Transcript of Elizabeth Mazzocchi Press Conference 8996 5Exelixis Announces January 10 Webcast of Presentation at the 26th Annual JPMorgan Healthcare Conference 2415 1Oncolytics Biotech Inc Announces Filing of Phase 1 2 Clinical Trial with REOLYSIN 28R 29 2411 1Oncolytics Biotech Inc Announces Filing of Phase 1 2 Clinical Trial with REOLYSIN 28R 29 2411 2The OCULUS Pachycam is the first compact and portable non-contact pachymeter with built-in keratometer. The OCULUS Pachycam has automatic correction of the IOP (intra ocular pressure) in accordance
...ologies - plus wavefront analysis - in one easy-to...a single device, you can obtain refraction, cornea...vefront analysis. The 3-D Wave allows you to evalu...ve and cataract surgery screenings, evaluate posto...
...re sensor and continues to lead the way. PressureW...measures pressure, temperature and flow. With sign..., it also serves as your primary guidewire, as wel...gh-performance guidewire. , Intracoronary pressu...
...nd and MRI-guided vacuum assisted breast biopsies ...d, FDA-cleared ATEC system for a faster, safer, ea... biopsy. Its compassionate care at its best for th...eful for biopsy and diagnostic excision of breast ...
Medicine Products: